

Translation

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2025 (Based on Japanese GAAP)

May 15, 2025

Company name: DAIKEN MEDICAL CO., LTD.
 Stock exchange listing: Tokyo
 Stock code: 7775 URL <https://daiken-iki.co.jp>
 Representative: President Keiichi Yamada
 Vice President, Chief of Headquarters
 Business Administration Division Masayuki Yamada TEL 06-6231-9917
 Inquiries: Masayuki Yamada
 Scheduled date of ordinary general meeting of shareholders: June 19, 2025
 Scheduled date to file Securities Report: June 19, 2025
 Scheduled date to commence dividend payments: June 2, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results meeting: Yes (for institutional investors and analysts)

(Amounts less than one million yen are rounded down)

1. Non-consolidated financial results for the year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(1) Non-consolidated operating results

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Year ended March 31, 2025	9,951	2.1	1,512	4.8	1,510	4.1	1,097	11.0
Year ended March 31, 2024	9,750	6.7	1,442	36.8	1,450	37.6	988	38.8

	Earnings per share	Diluted earnings per share	Profit/equity	Ordinary profit/total assets	Operating profit/net sales
	Yen	Yen	%	%	%
Year ended March 31, 2025	38.21	—	15.2	13.6	15.2
Year ended March 31, 2024	34.41	—	14.6	13.2	14.8

(2) Non-consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2025	11,181	7,515	66.9	260.53
As of March 31, 2024	11,006	7,022	63.5	243.32

(3) Non-consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Year ended March 31, 2025	1,120	(168)	(696)	2,995
Year ended March 31, 2024	1,555	(168)	(1,163)	2,739

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Dividend payout ratio (Non-consolidated)	Ratio of dividends to net assets (Non-consolidated)
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Year ended March 31, 2024	—	9.00	—	12.00	21.00	603	61.0	8.9
Year ended March 31, 2025	—	9.00	—	14.00	23.00	660	60.2	9.1
Year ending March 31, 2026 (Forecast)	—	9.00	—	11.00	20.00		82.1	

3. Forecast of non-consolidated financial results for the year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2025	5,120	4.2	460	(45.0)	455	(45.6)	320	(47.4)	11.14
Full year	10,500	5.5	1,010	(33.2)	1,000	(33.8)	700	(36.2)	24.37

4. Notes

(1) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

Changes in accounting policies due to other reasons: No

Changes in accounting estimates: No

Restatement of prior period financial statements: No

(2) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2025	31,840,000 shares	As of March 31, 2024	31,840,000 shares
----------------------	-------------------	----------------------	-------------------

Number of treasury shares at the end of the period

As of March 31, 2025	3,111,563 shares	As of March 31, 2024	3,111,563 shares
----------------------	------------------	----------------------	------------------

Average number of shares during the period

Year ended March 31, 2025	28,728,437 shares	Year ended March 31, 2024	28,728,439 shares
---------------------------	-------------------	---------------------------	-------------------

Non-consolidated financial statements
Non-consolidated balance sheets

(Thousands of yen)

	As of March 31, 2024	As of March 31, 2025
Assets		
Current assets		
Cash and deposits	2,739,141	2,995,993
Notes receivable - trade	68,087	43,231
Electronically recorded monetary claims - operating	1,272,477	1,293,656
Accounts receivable - trade	1,139,185	1,134,480
Finished goods	916,374	914,556
Work in process	80,436	102,094
Raw materials	441,237	413,414
Prepaid expenses	24,575	42,484
Other	49,516	45,198
Allowance for doubtful accounts	(93)	(94)
Total current assets	6,730,938	6,985,015
Non-current assets		
Property, plant and equipment		
Buildings, net	1,784,269	1,706,701
Structures, net	659	427
Machinery and equipment, net	192,773	200,883
Vehicles, net	1,310	739
Tools, furniture and fixtures, net	119,211	138,133
Land	1,703,670	1,703,670
Leased assets, net	14,431	7,058
Construction in progress	170,210	173,622
Total property, plant and equipment	3,986,537	3,931,237
Intangible assets		
Software	8,386	7,785
Telephone subscription right	5,103	5,103
Total intangible assets	13,489	12,888
Investments and other assets		
Investments in capital	10	10
Long-term prepaid expenses	7,070	5,242
Deferred tax assets	205,587	183,525
Guarantee deposits	52,287	52,762
Membership	13,100	13,100
Life insurance funds	8,797	8,797
Long-term accounts receivable - other	13,150	13,150
Allowance for doubtful accounts	(24,650)	(24,650)
Total investments and other assets	275,352	251,937
Total non-current assets	4,275,379	4,196,063
Total assets	11,006,318	11,181,079

(Thousands of yen)

	As of March 31, 2024	As of March 31, 2025
Liabilities		
Current liabilities		
Notes payable - trade	2,645	921
Electronically recorded obligations - operating	601,186	484,003
Accounts payable - trade	462,979	541,946
Short-term borrowings	1,080,000	720,000
Current portion of long-term borrowings	389,972	480,033
Accounts payable - other	313,219	240,309
Lease liabilities	8,238	4,469
Accrued expenses	65,426	69,930
Income taxes payable	252,070	198,032
Accrued consumption taxes	106,170	46,200
Deposits received	10,056	11,299
Notes payable - facilities	7,986	—
Electronically recorded obligations - facilities	26,037	26,183
Other	13,941	6,653
Total current liabilities	3,339,930	2,829,984
Non-current liabilities		
Long-term borrowings	623,423	818,390
Lease liabilities	8,028	3,558
Long-term guarantee deposits	9,955	11,473
Other	2,507	1,685
Total non-current liabilities	643,914	835,107
Total liabilities	3,983,844	3,665,091
Net assets		
Shareholders' equity		
Share capital	495,875	495,875
Capital surplus		
Legal capital surplus	400,875	400,875
Total capital surplus	400,875	400,875
Retained earnings		
Legal retained earnings	23,750	23,750
Other retained earnings		
General reserve	690,000	690,000
Retained earnings brought forward	7,206,373	7,700,696
Total retained earnings	7,920,123	8,414,446
Treasury shares	(1,826,584)	(1,826,584)
Total shareholders' equity	6,990,288	7,484,611
Share acquisition rights	32,185	31,375
Total net assets	7,022,474	7,515,987
Total liabilities and net assets	11,006,318	11,181,079

Non-consolidated statements of income

(Thousands of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Net sales	9,750,166	9,951,701
Cost of sales		
Beginning finished goods inventory	1,004,266	916,374
Cost of products manufactured	5,530,879	5,725,056
Cost of purchased goods	193,548	168,982
Cost of construction by the outside order	9,833	7,978
Total	6,738,527	6,818,392
Transfer to other account	53,971	49,105
Ending finished goods inventory	916,374	914,556
Total cost of sales	5,768,181	5,854,729
Gross profit	3,981,984	4,096,971
Selling, general and administrative expenses	2,539,343	2,584,897
Operating profit	1,442,640	1,512,073
Non-operating income		
Interest income	0	0
Commission income	1,036	1,098
Insurance fee income	445	3,395
Compensation income	3,965	1,418
Foreign exchange gains	2,908	—
Gain on forfeiture of unclaimed dividends	628	782
Gain on sale of scraps	2,355	315
Miscellaneous income	844	826
Total non-operating income	12,185	7,836
Non-operating expenses		
Interest expenses	4,825	9,364
Other	0	407
Total non-operating expenses	4,825	9,771
Ordinary profit	1,450,000	1,510,139
Extraordinary income		
Gain on reversal of share acquisition rights	—	809
Total extraordinary income	—	809
Extraordinary losses		
Loss on retirement of non-current assets	5,505	2,523
Loss on cancellation of leases	8,035	—
Total extraordinary losses	13,540	2,523
Profit before income taxes	1,436,459	1,508,425
Income taxes - current	422,848	388,742
Income taxes - deferred	25,008	22,062
Total income taxes	447,857	410,805
Profit	988,602	1,097,620

Non-consolidated statements of changes in equity

Fiscal year ended March 31, 2024

(Thousands of yen)

	Shareholders' equity						
	Share capital	Capital surplus		Retained earnings			
		Legal capital surplus	Total capital surplus	Legal retained earnings	Other retained earnings		Total retained earnings
					General reserve	Retained earnings brought forward	
Balance at beginning of period	495,875	400,875	400,875	23,750	690,000	6,792,339	7,506,089
Changes during period							
Dividends of surplus						(574,568)	(574,568)
Profit						988,602	988,602
Purchase of treasury shares							
Net changes in items other than shareholders' equity							
Total changes during period	—	—	—	—	—	414,033	414,033
Balance at end of period	495,875	400,875	400,875	23,750	690,000	7,206,373	7,920,123

	Shareholders' equity		Share acquisition rights	Total net assets
	Treasury shares	Total shareholders' equity		
Balance at beginning of period	(1,826,583)	6,576,256	20,890	6,597,146
Changes during period				
Dividends of surplus		(574,568)		(574,568)
Profit		988,602		988,602
Purchase of treasury shares	(1)	(1)		(1)
Net changes in items other than shareholders' equity			11,295	11,295
Total changes during period	(1)	414,032	11,295	425,327
Balance at end of period	(1,826,584)	6,990,288	32,185	7,022,474

Fiscal year ended March 31, 2025

(Thousands of yen)

	Shareholders' equity						
	Share capital	Capital surplus		Retained earnings			
		Legal capital surplus	Total capital surplus	Legal retained earnings	Other retained earnings		Total retained earnings
					General reserve	Retained earnings brought forward	
Balance at beginning of period	495,875	400,875	400,875	23,750	690,000	7,206,373	7,920,123
Changes during period							
Dividends of surplus						(603,297)	(603,297)
Profit						1,097,620	1,097,620
Purchase of treasury shares							
Net changes in items other than shareholders' equity							
Total changes during period	—	—	—	—	—	494,322	494,322
Balance at end of period	495,875	400,875	400,875	23,750	690,000	7,700,696	8,414,446

	Shareholders' equity		Share acquisition rights	Total net assets
	Treasury shares	Total shareholders' equity		
Balance at beginning of period	(1,826,584)	6,990,288	32,185	7,022,474
Changes during period				
Dividends of surplus		(603,297)		(603,297)
Profit		1,097,620		1,097,620
Purchase of treasury shares	—	—		—
Net changes in items other than shareholders' equity			(809)	(809)
Total changes during period	—	494,322	(809)	493,513
Balance at end of period	(1,826,584)	7,484,611	31,375	7,515,987

Non-consolidated statements of cash flows

(Thousands of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Cash flows from operating activities		
Profit before income taxes	1,436,459	1,508,425
Depreciation	214,276	232,597
Share-based payment expenses	11,295	–
Increase (decrease) in allowance for doubtful accounts	(1)	1
Interest and dividend income	(0)	(0)
Gain on reversal of share acquisition rights	–	(809)
Interest expenses	4,825	9,364
Decrease (increase) in trade receivables	50,777	8,381
Decrease (increase) in inventories	76,649	7,982
Increase (decrease) in trade payables	(50,405)	(39,940)
Loss on retirement of non-current assets	5,505	2,523
Loss on cancellation of leases	8,035	–
Decrease (increase) in accounts receivable - other	(1,786)	(3,202)
Increase (decrease) in accounts payable - other	175,627	(92,497)
Increase (decrease) in accrued expenses	(4,889)	4,507
Increase/decrease in consumption taxes payable/consumption taxes refund receivable	61,765	(59,969)
Other, net	10,907	(2,671)
Subtotal	1,999,041	1,574,692
Interest and dividends received	0	0
Interest paid	(4,903)	(10,083)
Income taxes paid	(438,637)	(443,700)
Net cash provided by (used in) operating activities	1,555,500	1,120,908
Cash flows from investing activities		
Purchase of property, plant and equipment	(161,900)	(166,508)
Purchase of intangible assets	(6,903)	(1,062)
Payments of guarantee deposits	(338)	(651)
Proceeds from refund of guarantee deposits	374	175
Net cash provided by (used in) investing activities	(168,767)	(168,046)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	80,000	(360,000)
Proceeds from long-term borrowings	–	750,000
Repayments of long-term borrowings	(659,972)	(464,972)
Purchase of treasury shares	(1)	–
Dividends paid	(573,955)	(612,799)
Repayments of lease liabilities	(9,875)	(8,238)
Net cash provided by (used in) financing activities	(1,163,804)	(696,009)
Net increase (decrease) in cash and cash equivalents	222,929	256,852
Cash and cash equivalents at beginning of period	2,516,212	2,739,141
Cash and cash equivalents at end of period	2,739,141	2,995,993